Xiaolei Su, PhD

Immune Signaling and Cancer Immunity

The Su Lab studies membrane remodeling and membrane-proximal signal transduction during immune responses. Using combined approaches of biochemical reconstitution, high resolution microscopy, and cell engineering, we aim to understand how spatial and temporal organization of membrane proteins and lipids regulates immune cell activation. These knowledges are leveraged to the development of new strategies and tools for cancer immunotherapy.

The cell membrane not only separates the intracellular space from the external environment, but also provides a platform for the processing and transduction of inter- or intra-cellular signals. The two-dimensional geometry, the interaction between proteins and lipids, and the local membrane curvature all converge to generate emergent properties of membrane-proximal signaling whereas the underlying mechanisms are not well understood. The T cell receptor (TCR) pathway represents a good example of this scenario. Although major components in the pathway have been identified, it remains unclear how individual components assemble and coordinate to build up a pathway for effectively receiving and amplifying signals from pathogenic antigens. The goal of our research program is to understand the general principals of membrane-proximal signaling under the biological context of T cell activation and other immune response processes.

How does phase separation regulate lipid signaling?

Our previous work identified T cell microclusters as phase separated structures driven by multivalent protein-protein interactions. These microclusters display liquid-like properties and contain the capability of organizing molecules to promote biochemical reactions such as actin polymerization. Beyond that, T cell microclusters reside underneath cell membranes. It remains totally unclear how these proteinaceous structures interact with lipids and regulating lipid metabolism. Questions we are interested in addressing includes:

• How do T cell microclusters regulate PIP2 turnover?
• How do charged lipids regulate T cell signaling?
• Mechanisms of leukemia-associated mutations in phospholipase C gamma

How does chimeric antigen receptor (CAR) activate T cells?

The chimeric antigen receptor (CAR) enables T cells to specifically target and kill cancer cells. Despite of its success in clinical trials, the cellular mechanism of how CAR is activated and how activated CAR triggers downstream signaling pathways remains unclear. The domain structure of CAR is very different from the endogenous T cell receptor (TCR), which raises the question of whether CAR activates T cells in a similar mechanism to TCR or not, and how the T cell signaling network accommodates a synthetic receptor. From the clinical side, so far major challenges of CAR-T cell therapy reside in poor infiltration, low persistency, frequent relapse, and severe side effects (cytokine storm and neurotoxicity). Understanding CAR signaling will provide clues to designing improved CARs for cancer therapy.

We have established a supported lipid bilayer system together with TIRF imaging for visualizing CAR signaling at high spatial and temporal resolutions. We are currently exploring the following questions:

• How is signaling amplified along the CAR pathway?
• How does phase separation affect CAR signaling?
• How to engineer CAR signaling for targeting solid tumors?